(20 days)
Immunoassay for the qualitative detection of barbiturates, benzodiazepine, phencyclidine, and/or their metabolites in human urine.
Not Found
The provided document is limited to a 510(k) clearance letter for the AccuSign® DOA3 (BZO/BAR/PCP) device, which is an immunoassay for the qualitative detection of certain drugs in human urine. A 510(k) clearance determines substantial equivalence to a legally marketed predicate device, but it does not typically include detailed information about the acceptance criteria and the specific study data that demonstrates the device meets those criteria.
Therefore, the requested information regarding acceptance criteria, reported device performance, sample sizes, ground truth establishment, expert involvement, and MRMC studies is not available within the provided document.
The document primarily states that the FDA reviewed the 510(k) notification and determined the device is substantially equivalent for the stated indications for use (qualitative detection of barbiturates, benzodiazepine, phencyclidine, and/or their metabolites in human urine).
To obtain the detailed study information you're asking for, one would typically need to refer to:
- The original 510(k) submission itself, which contains the test data and performance validation.
- The device's Instructions for Use (IFU) or package insert, which often includes performance characteristics.
- Scientific publications or clinical study reports if the manufacturer chose to publish the validation data.
Without these additional documents, I cannot fulfill your request for the specific study details.
{0}------------------------------------------------
Image /page/0/Picture/1 description: The image shows the logo for the U.S. Department of Health & Human Services. The logo consists of a circular seal with the text "DEPARTMENT OF HEALTH & HUMAN SERVICES • USA" arranged around the perimeter. Inside the circle is a stylized symbol that resembles a human figure with three flowing lines extending from the head, possibly representing growth or progress.
Public Health Service
APR 1 5 1999
Food and Drug Administration 9200 Corporate Boulevard Rockville MD 20850
Jemo Kang, Ph.D. President Princeton BioMeditech Corporation 4242 U.S. Route 1 Monmouth Junction, NJ 08852-1905
Re: K991076 Trade Name: AccuSign® DOA3 (BZO/BAR/PCP) Regulatory Class: II Product Code: DIS, JXM Dated: March 22, 1999 Received: March 26, 1999
Dear Dr. Kang:
We have reviewed your Section 510(k) notification of intent to market the device referenced above and we have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.
If your device is classified (see above) into either class II (Special Controls) or class III (Premarket Approval), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 895. A substantially equivalent determination assumes compliance with the Current Good Manufacturing Practice requirements, as set forth in the Quality System Regulation (QS) for Medical Devices: General regulation (21 CFR Part 820) and that, through periodic QS inspections, the Food and Drug Administration (FDA) will verify such assumptions. Failure to comply with the GMP regulation may result in regulatory action. In addition, FDA may publish further announcements concerning your device in the Federal Register. Please note: this response to your premarket notification submission does not affect any obligation you might have under sections 531 through 542 of the Act for devices under the Electronic Product Radiation Control provisions, or other Federal laws or regulations.
{1}------------------------------------------------
Page 2
Under the Clinical Laboratory Improvement Amendments of 1988 (CLIA-88), this device may require a CLIA complexity categorization. To determine if it does, you should contact the Centers for Disease Control and Prevention (CDC) at (770)488-7655.
This letter will allow you to begin marketing your device as described in your 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.
If you desire specific advice for your device on our labeling regulation (21 CFR Part 801 and additionally 809.10 for in vitro diagnostic devices), please contact the Office of Compliance at (301) 594-4588. Additionally, for questions on the promotion and advertising of your device, please contact the Office of Compliance at (301) 594-4639. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR 807.97). Other general information on your responsibilities under the Act may be obtained from the Division of Small Manufacturers Assistance at its toll free number (800) 638-2041 or at (301) 443-6597 or at its internet address "http://www.fda.gov/cdrh/dsmamain.html"
Sincerely yours,
Steven Sutman
Steven I. Gutman, M.D., M.B.A. Director Division of Clinical Laboratory Devices Office of Device Evaluation Center for Devices and Radiological Health
Enclosure
{2}------------------------------------------------
(k) Number (if known): _______________________________________________________________________________________________________________________________________________________
Device Name:___AccuSign® DOA3 (BZO/BAR/PCP)
Indications For Use:
ﺛﻴ
. .
Immunoassay for the qualitative detection of barbiturates, benzodiazepine, phencyclidine, and/or their metabolites in human urine.
Jean Copper
vision: ign-Off)
(vista Clinical Laboratory Devices
K991076
k) Number
(PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE IF NEEDED)
Concurrence of CDRH Office of Device Evaluation (ODE)
Professional Use:_X Prescription Use:_X (Per 21 CFR 801.109)
OR
Over The Counter Use: ________________________________________________________________________________________________________________________________________________________
(Optional Format 1-2-96)
§ 862.3150 Barbiturate test system.
(a)
Identification. A barbiturate test system is a device intended to measure barbiturates, a class of hypnotic and sedative drugs, in serum, urine, and gastric contents. Measurements obtained by this device are used in the diagnosis and treatment of barbiturate use or overdose and in monitoring levels of barbiturate to ensure appropriate therapy.(b)
Classification. Class II (special controls). A barbiturate test system is not exempt if it is intended for any use other than employment or insurance testing or is intended for Federal drug testing programs. The device is exempt from the premarket notification procedures in subpart E of part 807 of this chapter subject to the limitations in § 862.9, provided the test system is intended for employment and insurance testing and includes a statement in the labeling that the device is intended solely for use in employment and insurance testing, and does not include devices intended for Federal drug testing programs (e.g., programs run by the Substance Abuse and Mental Health Services Administration (SAMHSA), the Department of Transportation (DOT), and the U.S. military).